In vitro efficacy of AdTRAIL gene therapy of bladder cancer is enhanced by trichostatin A-mediated restoration of CAR expression and downregulation of cFLIP and Bcl-XL
Authors:
- P LuPLP Lu
- S J WhiteSWS J White
- C Voelkel-JohnsonCVC Voelkel-Johnson
- 16 September 2005
- journal article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 13 (3) , 281-289
Abstract
Current therapies for bladder cancer are suboptimal and adenoviral gene therapy has been explored as an alternative treatment. In this study, we evaluated the in vitro efficacy of an adenovirus expressing TNF-related apoptosis-inducing ligand (AdTRAIL). At low concentrations of virus, T24 cells were more resistant to AdTRAIL-induced apoptosis than 5637 bladder carcinoma cells. Resistance in T24 cells correlated with poor infectivity and lack of surface expression of coxsackie and adenovirus receptor (CAR). Pretreatment with low concentrations of the histone deacetylase inhibitor trichostatin A, restored CAR expression in T24 cells, which facilitated viral infection and resulted in apoptosis at low concentrations of AdTRAIL. In addition, trichostatin A reduced the expression of Bcl-X(L) and cFLIP resulting in increased sensitivity to recombinant TRAIL. Overexpression of cFLIP inhibited TRAIL-mediated killing in trichostatin A pretreated cells, indicating that downregulation of this antiapoptotic protein is required for sensitization. Therefore, trichostatin A can enhance the efficacy of AdTRAIL by restoring CAR expression and by generating a more pro-apoptotic phenotype that would facilitate bystander activity of TRAIL. Combination of histone deacetylase inhibitors with intravesical AdTRAIL gene therapy may be a novel treatment strategy for bladder cancer.Keywords
This publication has 36 references indexed in Scilit:
- Depsipeptide (FR901228) Enhances the Cytotoxic Activity of TRAIL by Redistributing TRAIL Receptor to Membrane Lipid RaftsMolecular Therapy, 2005
- Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignanciesCell Death & Differentiation, 2004
- In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancerCancer Gene Therapy, 2004
- Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21waf1Experimental Cell Research, 2004
- Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cellsCarcinogenesis, 2004
- Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cellsCancer Gene Therapy, 2004
- Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8–mediated apoptosis and down-regulation of c-FLIP proteinBlood, 2003
- Gene therapy progress and prospects: adenoviral vectorsGene Therapy, 2003
- The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling ComplexJournal of Biological Chemistry, 2002
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999